18. January 2011 17:23
NICE has extended its recommendations for the use of Aricept (donepezil), Reminyl (galantamine) Exelon (rivastigmine) and Ebixa (memantine) for the treatment of Alzheimer’s disease in draft guidance.
The Institute says that clinical trials have continued to show the “positive effects of the drugs” since they were first recommended in 2007.
Aricept, Reminyl and Exelon are all recommended for mild to moderate Alzheimer’s disease as treatment options. Ebixa is recommended for people with moderate Alzheimer’s who are intolerant of or have a contraindication to ACE inhibitors, or for people with severe cases.
Sir Andrew Dillon, NICE Chief Executive, said: “We are pleased to now be able to recommend these three drugs for both mild and moderate Alzheimer’s disease and another for moderate or severe Alzheimer’s, extending recommendations made in 2007.”
Final guidance is expected to be published in March 2011.